MARKET

VSTM

VSTM

Verastem
NASDAQ
7.36
-0.23
-3.03%
After Hours: 7.30 -0.06 -0.82% 16:55 12/08 EST
OPEN
7.59
PREV CLOSE
7.59
HIGH
7.80
LOW
7.31
VOLUME
67.09K
TURNOVER
0
52 WEEK HIGH
15.18
52 WEEK LOW
3.870
MARKET CAP
185.97M
P/E (TTM)
-1.8212
1D
5D
1M
3M
1Y
5Y
Verastem: Other preliminary proxy statements
Press release · 8h ago
Weekly Report: what happened at VSTM last week (1127-1201)?
Weekly Report · 4d ago
Weekly Report: what happened at VSTM last week (1120-1124)?
Weekly Report · 11/27 11:52
Verastem: Notice of Effectiveness
Press release · 11/21 17:02
BTIG Assumes Verastem at Buy, Announces Price Target of $27
Benzinga · 11/21 13:36
Analysts Offer Insights on Healthcare Companies: Enanta Pharmaceuticals (ENTA), Bluebird Bio (BLUE) and Verastem (VSTM)
3 analysts have maintained buy ratings on enanta pharmaceuticals, bluebird bio and verastem. Enanta has a buy rating from h.c. Wainwright and bluebird has a buy rating from jmp securities. Bluebird and verastem are in the healthcare sector.
TipRanks · 11/21 11:30
Weekly Report: what happened at VSTM last week (1113-1117)?
Weekly Report · 11/20 11:50
Where Verastem Stands With Analysts
Verastem has an average price target of $28.0 with a high of $36.00 and a low of $21.00. According to 4 analyst ratings in the last 3 months, verastem's stock has received a total of 4 bullish analyst ratings. The more positive the ratings, the more positive analysts are on the stock.
Benzinga · 11/15 17:01
More
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company’s pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, Avutometinib (VS-6766) and Defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, but not limited to low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, and melanoma. VS-6766 is an orally available small molecule RAF/MEK clamp. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.

Webull offers Verastem Inc stock information, including NASDAQ: VSTM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VSTM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VSTM stock methods without spending real money on the virtual paper trading platform.